Side-by-Side Comparison
BPC-157 vs GHK-Cu: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how BPC-157 and GHK-Cu differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
BPC-157
L2Also: Body Protection Compound-157, Bepecin, PL 14736
A gastric pentadecapeptide studied extensively in animal models for tissue healing, gut protection, and cytoprotective properties. Despite over 100 preclinical studies, human clinical data remains extremely limited.
GHK-Cu
L3Also: Copper Peptide, Glycyl-L-histidyl-L-lysine:copper(II), Copper Tripeptide-1
A naturally occurring copper-binding tripeptide with research supporting skin remodeling, wound healing, and anti-aging properties.
Side-by-side comparison
| Attribute | BPC-157 | GHK-Cu |
|---|---|---|
| Primary mechanism | Angiogenesis & VEGF Modulation | Copper-Dependent Gene Modulation |
| FDA status | Banned from Compounding (Category 2) | Research Only |
| Evidence level | Preclinical Evidence | Emerging Clinical Evidence |
| Human trials | Yes (3+ indexed) | Yes (5+ indexed) |
| Studies indexed | 128 total (3 human, 95 animal) | 96 total (8 human, 42 animal) |
| Primary uses researched | Tissue repair, Gut healing, Tendon recovery, Anti-inflammatory, Wound healing, Neuroprotection | Skin rejuvenation, Wound healing, Hair growth, Anti-aging |
| Administration routes | intramuscular, intraperitoneal (research), oral, subcutaneous, topical | subcutaneous, topical |
| Molecular weight | 1419.53 Da | 403.93 Da |
| Amino acids | 15 | 3 |
| Category | healing recovery | skin hair |
| WADA status | Prohibited | Permitted |
Key differences
Mechanism. BPC-157 acts primarily through angiogenesis & vegf modulation, while GHK-Cu acts primarily through copper-dependent gene modulation. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. BPC-157 is classified as banned from compounding (category 2); GHK-Cu is classified as research only. Regulatory status drives availability, legality, and the standard of evidence required for specific therapeutic claims.
Evidence base. GHK-Cu sits at a higher evidence level (L3) than BPC-157 (L2) under PeptideMark's L1–L5 methodology.
Research focus. Published research on BPC-157 has concentrated on tissue repair, gut healing, tendon recovery. Research on GHK-Cu has concentrated on skin rejuvenation, wound healing, hair growth. There is meaningful overlap between the two research programs, which is why these compounds are frequently compared.
Safety snapshot
| Attribute | BPC-157 | GHK-Cu |
|---|---|---|
| Documented effects | 7 total | 4 total |
| Serious events | 0 | 0 |
| Common events | 1 | 0 |
| Black box warning | No | No |
| Contraindications | 3 listed | 3 listed |
| Drug interactions | 3 flagged | 2 flagged |
| Most common event | Injection site reactions | — |
Strengths & limitations
BPC-157
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Restricted from compounding pharmacies (FDA Category 2)
- Limited evidence base (L2)
- Prohibited in competitive sport under WADA
GHK-Cu
Strengths
- Multiple human clinical trials (5+ indexed)
- Not on the WADA prohibited list
Limitations
- Not FDA-approved for any indication — research use only
Representative studies
BPC-157
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Vasireddi N, Hahamyan H, Salata MJ, et al. · Sports Health (2025)
Despite broad preclinical support across muscle, tendon, ligament, and bone models, only one clinical study exists for musculoskeletal applications, leaving a significant gap between animal and human evidence.
PubMed 40756949Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Lee KY, Burgess MM. · Alternative Therapies in Health and Medicine (2025)
Intravenous BPC-157 up to 20mg was well-tolerated in 2 healthy adults with no measurable effects on heart, liver, kidney, thyroid, or glucose biomarkers. Plasma levels returned to baseline within 24 hours.
PubMed 40131143GHK-Cu
GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration
Pickart L, Vasquez-Soltero JM, Margolina A. · BioMed Research International (2015)
GHK-Cu modulates 32% of human genes, upregulating repair/anti-inflammatory pathways and downregulating tissue destruction pathways — a broad anti-aging gene expression signature.
PubMed 25861628The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Pickart L, Vasquez-Soltero JM, Margolina A. · Oxidative Medicine and Cellular Longevity (2012)
GHK-Cu acts as a potent antioxidant and anti-degenerative agent through copper delivery, ECM remodeling, and upregulation of endogenous antioxidant defenses.
PubMed 22900137Frequently asked
What is the main difference between BPC-157 and GHK-Cu?
BPC-157 is a gastric pentadecapeptide studied extensively in animal models for tissue healing, gut protection, and cytoprotective properties. despite over 100 preclinical studies, human clinical data remains extremely limited. Its primary mechanism is angiogenesis & vegf modulation. GHK-Cu is a naturally occurring copper-binding tripeptide with research supporting skin remodeling, wound healing, and anti-aging properties. Its primary mechanism is copper-dependent gene modulation. The two differ in regulatory status (Banned from Compounding (Category 2) vs Research Only), strength of evidence (L2 vs L3), and the primary conditions for which each is researched.
Is BPC-157 or GHK-Cu FDA approved?
BPC-157: BPC-157 was placed on the FDA Category 2 list (substances with safety concerns) in late 2023, prohibiting compounding pharmacies from producing it for human use under Section 503A. The FDA cited potential immune reactions, manufacturing impurities, and a lack of human safety data. BPC-157 is not FDA-approved for any human indication. There is no legal basis for selling it as a drug, food, or dietary supplement. The FDA has stated it may take enforcement action against compounding pharmacies that produce it. Several legal challenges to the Category 2 classification are ongoing. GHK-Cu: Not FDA-approved as a drug. Available in cosmetic products. Not on Category 2 list. Research compound for injectable use.
How does the evidence base compare?
BPC-157 has 128 indexed studies (3 human, 95 animal) and is rated Preclinical Evidence. GHK-Cu has 96 indexed studies (8 human, 42 animal) and is rated Emerging Clinical Evidence. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can BPC-157 and GHK-Cu be compared directly?
BPC-157 and GHK-Cu come from different therapeutic categories (healing recovery vs skin hair), so direct clinical comparison is limited. Readers often compare them because of overlapping research interest, shared patient populations, or adjacent mechanisms — not because head-to-head trial data exists.
Are BPC-157 and GHK-Cu commonly stacked together?
There is no widely documented stacking protocol combining BPC-157 and GHK-Cu in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, BPC-157 or GHK-Cu?
BPC-157 has 7 documented side effects (0 serious). GHK-Cu has 4 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are BPC-157 and GHK-Cu administered?
BPC-157 is typically administered via intramuscular or intraperitoneal (research) or oral or subcutaneous or topical. GHK-Cu is typically administered via subcutaneous or topical. Route differences affect onset, peak levels, and patient convenience.
Which is better, BPC-157 or GHK-Cu?
"Better" depends on the therapeutic goal, regulatory context, and individual response. BPC-157 is most researched for tissue repair and gut healing; GHK-Cu is most researched for skin rejuvenation and wound healing. FDA status also matters: Banned from Compounding (Category 2) for BPC-157 vs Research Only for GHK-Cu. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
BPC-157 →
Full profile
GHK-Cu →